Roivant Sciences

Medalion helps hospitals to empower their practice for market expansion while maintaining compliance.

Gen-t is a Brazilian company founded in 2021, based in Sao Paulo, that focuses on genomic research through a diverse genetic biobank. The platform emphasizes the ethnic diversity of Brazil, providing researchers with access to genetic data that reflects the country's unique population admixture. This rich genetic resource aims to foster innovation across various fields, particularly in biotechnology, by enabling the development of more effective medicines and treatments tailored to the specific health needs of the Brazilian populace. Gen-t's efforts contribute to advancing the understanding of genetics and its applications in addressing diseases prevalent within the diverse Brazilian demographic.

Immunovant, Inc. is a clinical-stage biopharmaceutical company based in New York that specializes in developing monoclonal antibodies for treating autoimmune diseases. The company is advancing its primary investigational product, IMVT-1401, a fully human monoclonal antibody designed to selectively bind to and inhibit the neonatal fragment crystallizable receptor (FcRn). This product is currently undergoing Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, and it has also initiated Phase II trials for warm autoimmune hemolytic anemia. Immunovant aims to provide effective treatment options for patients with various IgG-mediated autoimmune disorders, allowing them to lead normal lives. It operates as a subsidiary of Roivant Sciences Ltd.

Silicon Therapeutics operates a computational drug discovery platform aimed at addressing challenging targets in drug development that are often deemed unattainable. The platform leverages advanced simulations of biological molecules based on the principles of physics, allowing for the prediction of interactions, energy states, and conformational behaviors of drug discovery targets. By utilizing insights from the innate immune system, Silicon Therapeutics enhances the understanding of the relationship between protein conformations and biological outcomes. This innovative approach enables institutions to conduct high-throughput drug discovery and design more effectively, ultimately advancing the field of pharmaceuticals.

Datavant, Inc. is a healthcare data platform that aggregates and analyzes biomedical data using machine learning and artificial intelligence. Founded in 2017 and based in San Francisco, the company focuses on enhancing the clinical trial process by organizing and structuring healthcare data to provide actionable insights. Datavant's services cater to the clinical development and commercial pharmaceutical sectors, as well as researchers, by facilitating the protection, matching, and sharing of health data. The platform is designed to help pharmaceutical companies manage privacy, security, compliance, and trust, thereby enabling safe data sharing and improving the design and interpretation of clinical trials.

Datavant, Inc. is a healthcare data platform that aggregates and analyzes biomedical data using machine learning and artificial intelligence. Founded in 2017 and based in San Francisco, the company focuses on enhancing the clinical trial process by organizing and structuring healthcare data to provide actionable insights. Datavant's services cater to the clinical development and commercial pharmaceutical sectors, as well as researchers, by facilitating the protection, matching, and sharing of health data. The platform is designed to help pharmaceutical companies manage privacy, security, compliance, and trust, thereby enabling safe data sharing and improving the design and interpretation of clinical trials.

Arbutus Biopharma Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing cures for chronic hepatitis B virus (HBV) infection. The company has a diverse pipeline that includes capsid inhibitors like AB-836, which aims to inhibit HBV replication, and AB-423, currently in pre-clinical studies. Additionally, Arbutus develops RNA interference (RNAi) therapeutics designed to reduce hepatitis B surface antigen levels in infected patients. Their portfolio also features AB-729, a targeted second-generation RNAi agent, and an orally active HBV RNA destabilizer that promotes RNA degradation. Arbutus is engaged in conducting clinical trials and various pre-clinical studies to evaluate the efficacy of its proprietary HBV therapies in combination with standard treatments. The company has established strategic alliances and collaborations with other organizations to enhance its research and development efforts. Headquartered in Warminster, Pennsylvania, Arbutus was previously known as Tekmira Pharmaceuticals Corporation before rebranding in July 2015.

Arbutus Biopharma Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing cures for chronic hepatitis B virus (HBV) infection. The company has a diverse pipeline that includes capsid inhibitors like AB-836, which aims to inhibit HBV replication, and AB-423, currently in pre-clinical studies. Additionally, Arbutus develops RNA interference (RNAi) therapeutics designed to reduce hepatitis B surface antigen levels in infected patients. Their portfolio also features AB-729, a targeted second-generation RNAi agent, and an orally active HBV RNA destabilizer that promotes RNA degradation. Arbutus is engaged in conducting clinical trials and various pre-clinical studies to evaluate the efficacy of its proprietary HBV therapies in combination with standard treatments. The company has established strategic alliances and collaborations with other organizations to enhance its research and development efforts. Headquartered in Warminster, Pennsylvania, Arbutus was previously known as Tekmira Pharmaceuticals Corporation before rebranding in July 2015.